Aim To determine the impact of pre-operative axillary ultrasound staging in a screen detected breast cancer population Materials and Method Ultrasound and needle biopsy staging results alongside reference standard sentinel lymph node biopsy and axillary lymph node dissection were retrospectively extracted from the unit's computer records between 01/04/2008 and 31/03/2015. Axillary staging was compared with final pathology and treatment. Results Of the 215,661 screening examinations performed, 780 invasive cancers were diagnosed which had pre-operative axillary staging data, of which 162 (20.7%) were node positive. 36 (4.6%) had a heavy nodal burden (3 or more nodes). 90 (11.5%) had an abnormal axillary ultrasound and axillary biopsy of which 54 were positive for cancer (33.3% of the node positive cases) and triaged to axillary lymph node dissection avoiding a sentinel lymph node biopsy. Of these 22 (40.7%) had neoadjuvant treatment, and 32 (59.3%) proceeded directly to axillary lymph node dissection. The sensitivity of axillary ultrasound and biopsy to detect women with a heavy nodal burden (3 or more nodes) was 41.7% (15 of 36). However, 17 (53%) of the 32 women with a positive axillary biopsy had a low burden of axillary disease (≤2 positive nodes) at axillary lymph node dissection, the mean number of nodes obtained was 14.6. Conclusion Significant numbers of women are being potentially overtreated or denied entry into Positive Sentinel Node: adjuvant therapy only vs adjuvant therapy and clearance or axillary radiotherapy (POSNOC) because of routine pre-operative axillary staging.
Reviewer #1:
In the discussion, I am a bit confused about line 123. Does the author mean, comparison with the other UK breast screening centres? The text is less well written from here on in.
This section has been rephrased and now reads

It is not easy to directly compare our results with the rest of the UK breast screening programme as the results of axillary staging have been reported in different ways in the NHSBSP and ABS audits of screen detected cancers over the period of this audit does not report in a comparable ways
Reviewer #2: I think there should be more acknowledgement in the Discussion and Limitations sections that, particularly given the relatively small number of heavily node positive women in this cohort, the fact that the pre-treatment nodal status of the 22 women with a positive axillary US biopsy receiving preoperative NAC is unknown means that there is potential for the actual accuracy of preoperative axillary assessment for heavy nodal disease to be markedly underestimated. There is no description of the differences in disease burden between those receiving NAC and those treated with primary surgery; it seems likely that in general the former had a heavier burden of disease and likelihood of heavier nodal positivity.
The following paragraph has been added to limitations
We can never accurately know the nodal burden of the 22 women with a positive core biopsy who received neo-adjuvant chemotherapy so our sensitivity and specificity for high nodal burden could be an under estimate, but this is true for all other papers who exclude neoadjuvant chemo therapy from their calculations. 13, 14, 16, 17 Re your last sentence regarding how ideally we would be able to predict which women would benefit from preoperative axillary staging: were you able to extract any trends from your data regarding this, e.g. relationship of tumour size to degree of nodal positivity in your patient cohort?
We Of the 215,661 screening examinations performed, 780 invasive cancers were diagnosed which had 11 pre-operative axillary staging data, of which 162 (20.7%) were node positive. 36 (4.6%) had a heavy 12 nodal burden (3 or more nodes). 90 (11.5%) had an abnormal axillary ultrasound and axillary biopsy 13 of which 54 were positive for cancer (33.3% of the node positive cases) and triaged to axillary lymph 14 node dissection avoiding a sentinel lymph node biopsy. Of these 22 (40.7%) had neoadjuvant 15 treatment, and 32 (59.3%) proceeded directly to axillary lymph node dissection. The sensitivity of 16 axillary ultrasound and biopsy to detect women with a heavy nodal burden (3 or more nodes) was 17 41.7% (15 of 36). However, 17 (53%) of the 32 women with a positive axillary biopsy had a low 18 burden of axillary disease (≤2 positive nodes) at axillary lymph node dissection, the mean number of 19 nodes obtained was 14.6. 20
Conclusion 21
Significant numbers of women are being potentially overtreated or denied entry into Positive 22 Multiple imaging modalities have been used to determine axillary status pre-operatively 9 13 but only axillary ultrasound with selective needle biopsy of morphologically abnormal nodes 14 {which has a specificity approaching 100%} is used routinely in clinical practice. 10, 11 The main 15 limitation of axillary ultrasound and needle biopsy is the relatively low sensitivity, which 16 varies widely according to the underlying prevalence of node positivity in the population 17 studied. 12,13,14 Additionally the more involved nodes an individual has at diagnosis the more 18 likely it is that the ultrasound needle biopsy will correctly make the diagnosis. 12 1), of these 36 (4.6%) had a heavy nodal burden (3 or more nodes) (table 1). 90 (11.5%) had 83 an abnormal axillary ultrasound and axillary biopsy of which 54 (60%) were positive for 84 cancer (33.3% of the node positive cases). Of these 54 women with a malignant axillary core 85 biopsy, 22 (40.7%) had neoadjuvant treatment followed by surgery to the breast and ALND, 86 and 32 (59.3%) proceeded directly to ALND. 15 (47%) of these women had more than 3 87 nodes positive (table 1) . In other words,sff 54 (7.1%) of 764 women with invasive cancer 88 were triaged to ALND avoiding a SLNB.
89
Of the 36 women with an abnormal axillary ultrasound but a negative core biopsy 9 (25%) 90 were node positive at SLNB and proceeded to ALND (figure 1). ALND rather than SLNB at 7.1% is lower than Houssami at 19.8% (11.6 -28.1%).
141
Even though we have a low risk population our ability to preferentially detect women with a 142 heavy disease burden is very similar to Van Wely's meta-analysis. 14 47% of our core biopsy Table 2 
